The stock of Aardvark Therapeutics Inc (AARD) has gone up by 45.25% for the week, with a 57.44% rise in the past month and a 70.56% rise in the past quarter. The volatility ratio for the week is 12.11%, and the volatility levels for the past 30 days are 6.56% for AARD. The simple moving average for the past 20 days is 37.06% for AARD’s stock, with a 50.57% simple moving average for the past 200 days.
Is It Worth Investing in Aardvark Therapeutics Inc (NASDAQ: AARD) Right Now?
Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AARD is 12.39M, and currently, shorts hold a 2.77% of that float. The average trading volume for AARD on June 25, 2025 was 76.79K shares.
AARD) stock’s latest price update
Aardvark Therapeutics Inc (NASDAQ: AARD)’s stock price has gone rise by 169641 in comparison to its previous close of 13.33, however, the company has experienced a 45.25% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-24 that SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona.
Analysts’ Opinion of AARD
Many brokerage firms have already submitted their reports for AARD stocks, with RBC Capital Mkts repeating the rating for AARD by listing it as a “Outperform.” The predicted price for AARD in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on March 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see AARD reach a price target of $29. The rating they have provided for AARD stocks is “Overweight” according to the report published on March 10th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to AARD, setting the target price at $50 in the report published on March 10th of the current year.
AARD Trading at 52.06% from the 50-Day Moving Average
After a stumble in the market that brought AARD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.51% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AARD starting from Decheng Capital Global Life Sc, who purchase 1,250,000 shares at the price of $16.00 back on Feb 14 ’25. After this action, Decheng Capital Global Life Sc now owns 2,958,887 shares of Aardvark Therapeutics Inc, valued at $20,000,000 using the latest closing price.
Lee Tien-Li, the Chief Executive Officer of Aardvark Therapeutics Inc, purchase 16,542 shares at $16.00 during a trade that took place back on Feb 14 ’25, which means that Lee Tien-Li is holding 1,496,175 shares at $264,672 based on the most recent closing price.
Stock Fundamentals for AARD
The total capital return value is set at -0.18. Equity return is now at value -110.36, with -46.77 for asset returns.
Based on Aardvark Therapeutics Inc (AARD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -33.37.
Currently, EBITDA for the company is -22.79 million with net debt to EBITDA at 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.86.
Conclusion
In conclusion, Aardvark Therapeutics Inc (AARD) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
